BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Epigentek Group Inc. Receives Notice of Allowance From The USPTO For Its Global DNA Methylation Quantification Methods


7/12/2010 3:08:14 PM

NEW YORK, July 12 - Epigentek Group Inc. announced today that the United States Patent and Trademark Office (USPTO) has awarded to the epigenetic tools company a Notice of Allowance for a patent to cover novel methods of rapid quantification of global DNA methylation.

DNA methylation plays a critical role in the regulation of gene function. Alteration of methylation has been proposed as a molecular marker in multiple biological processes such as cancer. Thus, the quantification of global methylation in cancer could provide very useful information for detection and analysis of this disease.

This key patent award strengthens Epigentek’s intellectual property and product portfolio, and further secures its global DNA methylation detection technologies.

The company also filed a related US patent application of a novel method to quantify hydroxymethylated DNA or 5-hydroxymethylcytosine (5-hmC) in a microplate-based, immunospecifically detecting format.

It is believed that 5-hmC plays an important role in switching genes on and off. Prior to Epigentek’s technology, there were no methods that could be used for practically or routinely identifying 5-hmC and discriminating 5-hydroxymethylcytosine from 5-methylcytosine. The presence of 5-hmC makes it necessary to not only re-evaluate existing DNA methylation data, but also necessary to determine relative distribution and changes of 5-hmC in human tissues of healthy and diseased statuses.

This new technology can be used for rapidly and accurately identifying hydroxymethylated DNA or 5-hmC in a high throughput format, suitable from any species including mammals, plants, fungi, bacteria, and viruses in a variety of forms including cultured cells, fresh and frozen tissues, paraffin-embedded tissues, plasma/serum samples, and body fluid samples.

About Epigentek Group Inc.

Epigentek is a leading biotechnology company that focuses on developing and providing innovative technologies and products as a complete and systematic solution for epigenetic related research and drug discovery. Visit our informative website at www.epigentek.com.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES